Finance

Lists
4521:TYO
Kaken Pharmaceutical Co Ltd
JP¥3 820,00
0,00%
(0,00) 1D
29 Sep., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4521...
Open
JP¥3 830
High
JP¥3 850
Low
JP¥3 810
Mkt. cap
168,61 mjd
Avg. vol.
113,02 k
Volume
107,70 k
Dividend
4,97%
Quarterly dividend
JPÂ¥48
Ex-dividend date
29 Sep. 2026
P/E ratio
14,03
52-wk high
JP¥4 445
52-wk low
JP¥3 540
EPS
JPÂ¥272
Shares outstanding
39,72 m
No. of employees
1 k
Open
JP¥3 830
High
JP¥3 850
Low
JP¥3 810
Mkt. cap
168,61 mjd
Avg. vol.
113,02 k
Volume
107,70 k
Dividend
4,97%
Quarterly dividend
JPÂ¥48
Ex-dividend date
29 Sep. 2026
P/E ratio
14,03
52-wk high
JP¥4 445
52-wk low
JP¥3 540
EPS
JPÂ¥272
Shares outstanding
39,72 m
No. of employees
1 k
About Kaken Pharmaceutical Co Ltd
CEO-
Employees1,11 k
Founded1917
Headquarters-
SectorPharmaceutical industry
Last report
07 Aug. 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
30,16 mjd / -
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
20,49 mjd
18,26 mjd
19,25 mjd
30,16 mjd
Cost of goods sold
8,78 mjd
9,01 mjd
10,09 mjd
9,18 mjd
Cost of revenue
8,78 mjd
9,01 mjd
10,09 mjd
9,18 mjd
Research and development expenses
6,29 mjd
3,97 mjd
4,94 mjd
4,60 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,23 mjd
4,92 mjd
4,92 mjd
5,47 mjd
Operating expense
11,52 mjd
8,90 mjd
10,62 mjd
10,07 mjd
Total operating expenses
20,30 mjd
17,91 mjd
20,71 mjd
19,25 mjd
Operating income
187,00 m
354,00 m
-1,46 mjd
10,90 mjd
Other non operating income
-27,00 m
34,00 m
43,00 m
8,00 m
EBT including unusual items
988,00 m
588,00 m
328,00 m
11,24 mjd
EBT excluding unusual items
184,00 m
598,00 m
-1,41 mjd
11,26 mjd
Income tax expense
267,00 m
182,00 m
-418,00 m
2,80 mjd
Effective tax rate
27,02%
-
-127,44%
24,93%
Other operating expenses
-
-
-
-
Net income
721,00 m
406,00 m
746,00 m
8,44 mjd
Net profit margin
3,52%
-
3,87%
27,99%
Earnings per share
-
-
-
-
Interest and investment income
78,00 m
324,00 m
91,00 m
393,00 m
Interest expense
-11,00 m
-11,00 m
-13,00 m
-14,00 m
Net interest expenses
67,00 m
313,00 m
78,00 m
379,00 m
Depreciation and amortization charges
-
-
752,00 m
-
EBITDA
922,00 m
992,50 m
-624,75 m
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme